nodes	percent_of_prediction	percent_of_DWPC	metapath
Gemcitabine—ABCB1—Lisinopril—dilated cardiomyopathy	0.0973	0.532	CbGbCtD
Gemcitabine—ABCB1—Spironolactone—dilated cardiomyopathy	0.0856	0.468	CbGbCtD
Gemcitabine—Breast cancer—Spironolactone—dilated cardiomyopathy	0.0247	0.0576	CcSEcCtD
Gemcitabine—SLC29A2—cardiac ventricle—dilated cardiomyopathy	0.0166	0.0697	CbGeAlD
Gemcitabine—CMPK1—cardiac ventricle—dilated cardiomyopathy	0.0158	0.0663	CbGeAlD
Gemcitabine—SLC29A2—myocardium—dilated cardiomyopathy	0.0156	0.0656	CbGeAlD
Gemcitabine—CMPK1—myocardium—dilated cardiomyopathy	0.0148	0.0624	CbGeAlD
Gemcitabine—POLD1—heart—dilated cardiomyopathy	0.013	0.0546	CbGeAlD
Gemcitabine—CDA—heart—dilated cardiomyopathy	0.0117	0.049	CbGeAlD
Gemcitabine—SLC29A2—heart—dilated cardiomyopathy	0.0109	0.0458	CbGeAlD
Gemcitabine—ABCC10—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.0106	0.0711	CbGpPWpGaD
Gemcitabine—CMPK1—heart—dilated cardiomyopathy	0.0104	0.0436	CbGeAlD
Gemcitabine—RRM1—cardiac ventricle—dilated cardiomyopathy	0.0101	0.0425	CbGeAlD
Gemcitabine—POLE—heart—dilated cardiomyopathy	0.00971	0.0408	CbGeAlD
Gemcitabine—Ulcer—Spironolactone—dilated cardiomyopathy	0.00954	0.0222	CcSEcCtD
Gemcitabine—RRM1—myocardium—dilated cardiomyopathy	0.00952	0.04	CbGeAlD
Gemcitabine—SLC29A2—cardiac atrium—dilated cardiomyopathy	0.00932	0.0392	CbGeAlD
Gemcitabine—Vasculitis—Spironolactone—dilated cardiomyopathy	0.00924	0.0215	CcSEcCtD
Gemcitabine—CMPK1—cardiac atrium—dilated cardiomyopathy	0.00886	0.0372	CbGeAlD
Gemcitabine—POLA1—heart—dilated cardiomyopathy	0.00837	0.0352	CbGeAlD
Gemcitabine—SLC29A1—cardiac ventricle—dilated cardiomyopathy	0.00823	0.0346	CbGeAlD
Gemcitabine—Eruption—Furosemide—dilated cardiomyopathy	0.00798	0.0186	CcSEcCtD
Gemcitabine—Lung infiltration—Lisinopril—dilated cardiomyopathy	0.00785	0.0183	CcSEcCtD
Gemcitabine—SLC29A1—myocardium—dilated cardiomyopathy	0.00774	0.0325	CbGeAlD
Gemcitabine—Hypomagnesaemia—Furosemide—dilated cardiomyopathy	0.00773	0.018	CcSEcCtD
Gemcitabine—ABCC10—cardiac ventricle—dilated cardiomyopathy	0.00749	0.0315	CbGeAlD
Gemcitabine—DCK—myocardium—dilated cardiomyopathy	0.00739	0.0311	CbGeAlD
Gemcitabine—RRM1—heart—dilated cardiomyopathy	0.00664	0.0279	CbGeAlD
Gemcitabine—Generalised oedema—Lisinopril—dilated cardiomyopathy	0.00619	0.0144	CcSEcCtD
Gemcitabine—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.0059	0.0137	CcSEcCtD
Gemcitabine—RRM1—cardiac atrium—dilated cardiomyopathy	0.00568	0.0239	CbGeAlD
Gemcitabine—SLC29A1—heart—dilated cardiomyopathy	0.0054	0.0227	CbGeAlD
Gemcitabine—Hypocalcaemia—Furosemide—dilated cardiomyopathy	0.00536	0.0125	CcSEcCtD
Gemcitabine—Drug interaction—Furosemide—dilated cardiomyopathy	0.00529	0.0123	CcSEcCtD
Gemcitabine—DCK—heart—dilated cardiomyopathy	0.00516	0.0217	CbGeAlD
Gemcitabine—Hearing impaired—Furosemide—dilated cardiomyopathy	0.00516	0.012	CcSEcCtD
Gemcitabine—Influenza-like symptoms—Lisinopril—dilated cardiomyopathy	0.00516	0.012	CcSEcCtD
Gemcitabine—Vasculitis—Furosemide—dilated cardiomyopathy	0.00503	0.0117	CcSEcCtD
Gemcitabine—Stevens-Johnson syndrome—Spironolactone—dilated cardiomyopathy	0.005	0.0116	CcSEcCtD
Gemcitabine—Renal failure—Spironolactone—dilated cardiomyopathy	0.00496	0.0115	CcSEcCtD
Gemcitabine—ABCC10—heart—dilated cardiomyopathy	0.00492	0.0207	CbGeAlD
Gemcitabine—Pleural effusion—Lisinopril—dilated cardiomyopathy	0.00481	0.0112	CcSEcCtD
Gemcitabine—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.00471	0.011	CcSEcCtD
Gemcitabine—SLC29A1—cardiac atrium—dilated cardiomyopathy	0.00462	0.0194	CbGeAlD
Gemcitabine—DCK—cardiac atrium—dilated cardiomyopathy	0.00441	0.0185	CbGeAlD
Gemcitabine—Erythema multiforme—Spironolactone—dilated cardiomyopathy	0.00428	0.00997	CcSEcCtD
Gemcitabine—ABCC10—cardiac atrium—dilated cardiomyopathy	0.0042	0.0177	CbGeAlD
Gemcitabine—Proteinuria—Lisinopril—dilated cardiomyopathy	0.00419	0.00976	CcSEcCtD
Gemcitabine—Protein urine present—Lisinopril—dilated cardiomyopathy	0.00413	0.00962	CcSEcCtD
Gemcitabine—Alopecia—Spironolactone—dilated cardiomyopathy	0.004	0.00932	CcSEcCtD
Gemcitabine—Deafness—Furosemide—dilated cardiomyopathy	0.00398	0.00927	CcSEcCtD
Gemcitabine—Drug interaction—Lisinopril—dilated cardiomyopathy	0.00397	0.00924	CcSEcCtD
Gemcitabine—Creatinine increased—Lisinopril—dilated cardiomyopathy	0.00387	0.009	CcSEcCtD
Gemcitabine—CMPK1—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.0038	0.0254	CbGpPWpGaD
Gemcitabine—Vasculitis—Lisinopril—dilated cardiomyopathy	0.00377	0.00878	CcSEcCtD
Gemcitabine—Dermatitis bullous—Furosemide—dilated cardiomyopathy	0.00373	0.00868	CcSEcCtD
Gemcitabine—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.00368	0.00857	CcSEcCtD
Gemcitabine—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00366	0.00852	CcSEcCtD
Gemcitabine—Influenza like illness—Lisinopril—dilated cardiomyopathy	0.00358	0.00832	CcSEcCtD
Gemcitabine—Malaise—Spironolactone—dilated cardiomyopathy	0.00356	0.00828	CcSEcCtD
Gemcitabine—Leukopenia—Spironolactone—dilated cardiomyopathy	0.00353	0.00822	CcSEcCtD
Gemcitabine—Fluid retention—Lisinopril—dilated cardiomyopathy	0.0035	0.00814	CcSEcCtD
Gemcitabine—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.00348	0.00809	CcSEcCtD
Gemcitabine—Neuropathy—Lisinopril—dilated cardiomyopathy	0.00346	0.00805	CcSEcCtD
Gemcitabine—Blood creatinine increased—Furosemide—dilated cardiomyopathy	0.00334	0.00777	CcSEcCtD
Gemcitabine—Discomfort—Spironolactone—dilated cardiomyopathy	0.00332	0.00772	CcSEcCtD
Gemcitabine—SLC28A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.0033	0.0221	CbGpPWpGaD
Gemcitabine—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.00328	0.00763	CcSEcCtD
Gemcitabine—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.00324	0.00755	CcSEcCtD
Gemcitabine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00322	0.00749	CcSEcCtD
Gemcitabine—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.00321	0.00747	CcSEcCtD
Gemcitabine—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.00315	0.00734	CcSEcCtD
Gemcitabine—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.00306	0.00712	CcSEcCtD
Gemcitabine—Hepatic failure—Lisinopril—dilated cardiomyopathy	0.00298	0.00692	CcSEcCtD
Gemcitabine—Somnolence—Spironolactone—dilated cardiomyopathy	0.00286	0.00666	CcSEcCtD
Gemcitabine—Renal impairment—Lisinopril—dilated cardiomyopathy	0.00281	0.00654	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.00278	0.00647	CcSEcCtD
Gemcitabine—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.00278	0.00647	CcSEcCtD
Gemcitabine—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.00276	0.00643	CcSEcCtD
Gemcitabine—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.00273	0.00635	CcSEcCtD
Gemcitabine—DCK—Purine metabolism—GPX1—dilated cardiomyopathy	0.00273	0.0182	CbGpPWpGaD
Gemcitabine—Stevens-Johnson syndrome—Furosemide—dilated cardiomyopathy	0.00272	0.00634	CcSEcCtD
Gemcitabine—Renal failure—Furosemide—dilated cardiomyopathy	0.0027	0.00628	CcSEcCtD
Gemcitabine—SLC29A2—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00269	0.018	CbGpPWpGaD
Gemcitabine—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.00265	0.00617	CcSEcCtD
Gemcitabine—Sweating—Furosemide—dilated cardiomyopathy	0.00263	0.00613	CcSEcCtD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00261	0.0175	CbGpPWpGaD
Gemcitabine—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.0026	0.00604	CcSEcCtD
Gemcitabine—Face oedema—Lisinopril—dilated cardiomyopathy	0.00258	0.00601	CcSEcCtD
Gemcitabine—TYMS—Circadian rythm related genes—SIK1—dilated cardiomyopathy	0.00257	0.0172	CbGpPWpGaD
Gemcitabine—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.00256	0.00596	CcSEcCtD
Gemcitabine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.00254	0.00592	CcSEcCtD
Gemcitabine—Blood creatinine increased—Lisinopril—dilated cardiomyopathy	0.0025	0.00583	CcSEcCtD
Gemcitabine—SLC28A3—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.0025	0.0167	CbGpPWpGaD
Gemcitabine—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.00243	0.00567	CcSEcCtD
Gemcitabine—Urethral disorder—Furosemide—dilated cardiomyopathy	0.00242	0.00562	CcSEcCtD
Gemcitabine—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.00241	0.0056	CcSEcCtD
Gemcitabine—CDA—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00235	0.0157	CbGpPWpGaD
Gemcitabine—Erythema multiforme—Furosemide—dilated cardiomyopathy	0.00233	0.00542	CcSEcCtD
Gemcitabine—Influenza—Lisinopril—dilated cardiomyopathy	0.00231	0.00538	CcSEcCtD
Gemcitabine—Pruritus—Spironolactone—dilated cardiomyopathy	0.00228	0.0053	CcSEcCtD
Gemcitabine—Bronchospasm—Lisinopril—dilated cardiomyopathy	0.00227	0.00529	CcSEcCtD
Gemcitabine—Angiopathy—Furosemide—dilated cardiomyopathy	0.00224	0.0052	CcSEcCtD
Gemcitabine—Immune system disorder—Furosemide—dilated cardiomyopathy	0.00223	0.00518	CcSEcCtD
Gemcitabine—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.0022	0.00513	CcSEcCtD
Gemcitabine—Arrhythmia—Furosemide—dilated cardiomyopathy	0.0022	0.00512	CcSEcCtD
Gemcitabine—Pancytopenia—Lisinopril—dilated cardiomyopathy	0.00219	0.00511	CcSEcCtD
Gemcitabine—Neutropenia—Lisinopril—dilated cardiomyopathy	0.00216	0.00503	CcSEcCtD
Gemcitabine—Erythema—Furosemide—dilated cardiomyopathy	0.00215	0.00499	CcSEcCtD
Gemcitabine—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.00208	0.00485	CcSEcCtD
Gemcitabine—Pneumonia—Lisinopril—dilated cardiomyopathy	0.00207	0.00482	CcSEcCtD
Gemcitabine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00205	0.00476	CcSEcCtD
Gemcitabine—Stevens-Johnson syndrome—Lisinopril—dilated cardiomyopathy	0.00204	0.00475	CcSEcCtD
Gemcitabine—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.00203	0.00473	CcSEcCtD
Gemcitabine—Rash—Spironolactone—dilated cardiomyopathy	0.00203	0.00472	CcSEcCtD
Gemcitabine—Dermatitis—Spironolactone—dilated cardiomyopathy	0.00203	0.00472	CcSEcCtD
Gemcitabine—Renal failure—Lisinopril—dilated cardiomyopathy	0.00203	0.00471	CcSEcCtD
Gemcitabine—Neuropathy peripheral—Lisinopril—dilated cardiomyopathy	0.00202	0.0047	CcSEcCtD
Gemcitabine—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.00202	0.0047	CcSEcCtD
Gemcitabine—Headache—Spironolactone—dilated cardiomyopathy	0.00202	0.00469	CcSEcCtD
Gemcitabine—Anaemia—Furosemide—dilated cardiomyopathy	0.00198	0.00462	CcSEcCtD
Gemcitabine—Sweating—Lisinopril—dilated cardiomyopathy	0.00198	0.0046	CcSEcCtD
Gemcitabine—Haematuria—Lisinopril—dilated cardiomyopathy	0.00196	0.00457	CcSEcCtD
Gemcitabine—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.00195	0.00453	CcSEcCtD
Gemcitabine—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.00192	0.00447	CcSEcCtD
Gemcitabine—Leukopenia—Furosemide—dilated cardiomyopathy	0.00192	0.00447	CcSEcCtD
Gemcitabine—Nausea—Spironolactone—dilated cardiomyopathy	0.00191	0.00445	CcSEcCtD
Gemcitabine—SLC29A1—SLC-mediated transmembrane transport—SLC22A5—dilated cardiomyopathy	0.00187	0.0125	CbGpPWpGaD
Gemcitabine—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00185	0.00432	CcSEcCtD
Gemcitabine—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.00184	0.00427	CcSEcCtD
Gemcitabine—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.00183	0.00425	CcSEcCtD
Gemcitabine—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.00182	0.00424	CcSEcCtD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.00181	0.00422	CcSEcCtD
Gemcitabine—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.00181	0.00422	CcSEcCtD
Gemcitabine—RRM1—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00178	0.0119	CbGpPWpGaD
Gemcitabine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.00175	0.00408	CcSEcCtD
Gemcitabine—Erythema multiforme—Lisinopril—dilated cardiomyopathy	0.00175	0.00407	CcSEcCtD
Gemcitabine—SLC28A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00172	0.0115	CbGpPWpGaD
Gemcitabine—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.00172	0.004	CcSEcCtD
Gemcitabine—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.00171	0.00399	CcSEcCtD
Gemcitabine—Skin disorder—Furosemide—dilated cardiomyopathy	0.0017	0.00396	CcSEcCtD
Gemcitabine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.00169	0.00394	CcSEcCtD
Gemcitabine—Angiopathy—Lisinopril—dilated cardiomyopathy	0.00168	0.00391	CcSEcCtD
Gemcitabine—SLC28A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00168	0.0112	CbGpPWpGaD
Gemcitabine—SLC28A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00168	0.0112	CbGpPWpGaD
Gemcitabine—Anorexia—Furosemide—dilated cardiomyopathy	0.00167	0.00389	CcSEcCtD
Gemcitabine—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.00167	0.00388	CcSEcCtD
Gemcitabine—Chills—Lisinopril—dilated cardiomyopathy	0.00166	0.00386	CcSEcCtD
Gemcitabine—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.00165	0.00385	CcSEcCtD
Gemcitabine—Hypotension—Furosemide—dilated cardiomyopathy	0.00164	0.00381	CcSEcCtD
Gemcitabine—Alopecia—Lisinopril—dilated cardiomyopathy	0.00163	0.0038	CcSEcCtD
Gemcitabine—Erythema—Lisinopril—dilated cardiomyopathy	0.00161	0.00375	CcSEcCtD
Gemcitabine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.00157	0.00366	CcSEcCtD
Gemcitabine—SLC28A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00156	0.0104	CbGpPWpGaD
Gemcitabine—Back pain—Lisinopril—dilated cardiomyopathy	0.00156	0.00362	CcSEcCtD
Gemcitabine—Somnolence—Furosemide—dilated cardiomyopathy	0.00156	0.00362	CcSEcCtD
Gemcitabine—ABCB1—ABC-family proteins mediated transport—ABCC9—dilated cardiomyopathy	0.00154	0.0103	CbGpPWpGaD
Gemcitabine—Decreased appetite—Furosemide—dilated cardiomyopathy	0.00152	0.00354	CcSEcCtD
Gemcitabine—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00151	0.00352	CcSEcCtD
Gemcitabine—Fatigue—Furosemide—dilated cardiomyopathy	0.00151	0.00351	CcSEcCtD
Gemcitabine—Pain—Furosemide—dilated cardiomyopathy	0.0015	0.00349	CcSEcCtD
Gemcitabine—Constipation—Furosemide—dilated cardiomyopathy	0.0015	0.00349	CcSEcCtD
Gemcitabine—CMPK1—Metabolism—ANKRD1—dilated cardiomyopathy	0.0015	0.01	CbGpPWpGaD
Gemcitabine—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.00149	0.00348	CcSEcCtD
Gemcitabine—Anaemia—Lisinopril—dilated cardiomyopathy	0.00149	0.00346	CcSEcCtD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00147	0.00983	CbGpPWpGaD
Gemcitabine—RRM2—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00147	0.00981	CbGpPWpGaD
Gemcitabine—POLE—Mitotic M-M/G1 phases—EMD—dilated cardiomyopathy	0.00146	0.00976	CbGpPWpGaD
Gemcitabine—Malaise—Lisinopril—dilated cardiomyopathy	0.00145	0.00338	CcSEcCtD
Gemcitabine—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.00144	0.00336	CcSEcCtD
Gemcitabine—Leukopenia—Lisinopril—dilated cardiomyopathy	0.00144	0.00335	CcSEcCtD
Gemcitabine—ABCB1—heart—dilated cardiomyopathy	0.00142	0.00597	CbGeAlD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.00141	0.00942	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—TAZ—dilated cardiomyopathy	0.00141	0.0094	CbGpPWpGaD
Gemcitabine—SLC29A2—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00141	0.0094	CbGpPWpGaD
Gemcitabine—Cough—Lisinopril—dilated cardiomyopathy	0.00141	0.00327	CcSEcCtD
Gemcitabine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.00138	0.00322	CcSEcCtD
Gemcitabine—Arthralgia—Lisinopril—dilated cardiomyopathy	0.00137	0.00319	CcSEcCtD
Gemcitabine—Myalgia—Lisinopril—dilated cardiomyopathy	0.00137	0.00319	CcSEcCtD
Gemcitabine—Chest pain—Lisinopril—dilated cardiomyopathy	0.00137	0.00319	CcSEcCtD
Gemcitabine—DCK—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.00137	0.00916	CbGpPWpGaD
Gemcitabine—SLC29A2—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00137	0.00914	CbGpPWpGaD
Gemcitabine—SLC29A2—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00137	0.00914	CbGpPWpGaD
Gemcitabine—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.00136	0.00317	CcSEcCtD
Gemcitabine—Discomfort—Lisinopril—dilated cardiomyopathy	0.00135	0.00315	CcSEcCtD
Gemcitabine—Oedema—Lisinopril—dilated cardiomyopathy	0.00131	0.00306	CcSEcCtD
Gemcitabine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.00131	0.00306	CcSEcCtD
Gemcitabine—SLC28A3—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00131	0.00874	CbGpPWpGaD
Gemcitabine—Infection—Lisinopril—dilated cardiomyopathy	0.00131	0.00304	CcSEcCtD
Gemcitabine—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.00129	0.00299	CcSEcCtD
Gemcitabine—Skin disorder—Lisinopril—dilated cardiomyopathy	0.00128	0.00297	CcSEcCtD
Gemcitabine—RRM2—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00128	0.00854	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—SDHA—dilated cardiomyopathy	0.00127	0.0085	CbGpPWpGaD
Gemcitabine—SLC29A2—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00127	0.0085	CbGpPWpGaD
Gemcitabine—SLC28A3—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.00127	0.0085	CbGpPWpGaD
Gemcitabine—SLC28A3—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.00127	0.0085	CbGpPWpGaD
Gemcitabine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00127	0.00296	CcSEcCtD
Gemcitabine—POLD1—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00127	0.00848	CbGpPWpGaD
Gemcitabine—Asthenia—Furosemide—dilated cardiomyopathy	0.00126	0.00292	CcSEcCtD
Gemcitabine—Anorexia—Lisinopril—dilated cardiomyopathy	0.00125	0.00292	CcSEcCtD
Gemcitabine—Pruritus—Furosemide—dilated cardiomyopathy	0.00124	0.00288	CcSEcCtD
Gemcitabine—ABCC10—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.00123	0.00822	CbGpPWpGaD
Gemcitabine—Hypotension—Lisinopril—dilated cardiomyopathy	0.00123	0.00286	CcSEcCtD
Gemcitabine—POLE—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.00123	0.00819	CbGpPWpGaD
Gemcitabine—Diarrhoea—Furosemide—dilated cardiomyopathy	0.0012	0.00279	CcSEcCtD
Gemcitabine—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.0012	0.00279	CcSEcCtD
Gemcitabine—ABCC10—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.0012	0.00799	CbGpPWpGaD
Gemcitabine—ABCC10—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.0012	0.00799	CbGpPWpGaD
Gemcitabine—Insomnia—Lisinopril—dilated cardiomyopathy	0.00119	0.00277	CcSEcCtD
Gemcitabine—SLC28A3—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00118	0.0079	CbGpPWpGaD
Gemcitabine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.00118	0.00275	CcSEcCtD
Gemcitabine—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00117	0.00273	CcSEcCtD
Gemcitabine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00117	0.00272	CcSEcCtD
Gemcitabine—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.00114	0.00266	CcSEcCtD
Gemcitabine—RRM2—Cell Cycle—TUBB—dilated cardiomyopathy	0.00114	0.00763	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00114	0.00761	CbGpPWpGaD
Gemcitabine—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.00113	0.00264	CcSEcCtD
Gemcitabine—POLD1—Cell Cycle—TUBB—dilated cardiomyopathy	0.00113	0.00759	CbGpPWpGaD
Gemcitabine—Fatigue—Lisinopril—dilated cardiomyopathy	0.00113	0.00264	CcSEcCtD
Gemcitabine—POLD1—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00113	0.00756	CbGpPWpGaD
Gemcitabine—Pain—Lisinopril—dilated cardiomyopathy	0.00112	0.00262	CcSEcCtD
Gemcitabine—Constipation—Lisinopril—dilated cardiomyopathy	0.00112	0.00262	CcSEcCtD
Gemcitabine—Vomiting—Furosemide—dilated cardiomyopathy	0.00111	0.00259	CcSEcCtD
Gemcitabine—ABCC10—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00111	0.00743	CbGpPWpGaD
Gemcitabine—Rash—Furosemide—dilated cardiomyopathy	0.0011	0.00257	CcSEcCtD
Gemcitabine—Dermatitis—Furosemide—dilated cardiomyopathy	0.0011	0.00257	CcSEcCtD
Gemcitabine—Headache—Furosemide—dilated cardiomyopathy	0.0011	0.00255	CcSEcCtD
Gemcitabine—POLE—Cell Cycle—TUBB—dilated cardiomyopathy	0.0011	0.00733	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.00109	0.0073	CbGpPWpGaD
Gemcitabine—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.00108	0.00252	CcSEcCtD
Gemcitabine—RRM2—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00107	0.00715	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00106	0.00711	CbGpPWpGaD
Gemcitabine—POLA1—Mitotic M-M/G1 phases—EMD—dilated cardiomyopathy	0.00104	0.00696	CbGpPWpGaD
Gemcitabine—Nausea—Furosemide—dilated cardiomyopathy	0.00104	0.00242	CcSEcCtD
Gemcitabine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.00104	0.00242	CcSEcCtD
Gemcitabine—POLE—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.00103	0.00687	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—EMD—dilated cardiomyopathy	0.00102	0.0068	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—EMD—dilated cardiomyopathy	0.00101	0.00676	CbGpPWpGaD
Gemcitabine—RRM1—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000993	0.00664	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—EMD—dilated cardiomyopathy	0.000976	0.00653	CbGpPWpGaD
Gemcitabine—SLC29A1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000974	0.00652	CbGpPWpGaD
Gemcitabine—TYMS—Nucleotide metabolism—GPX1—dilated cardiomyopathy	0.000961	0.00643	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—ALMS1—dilated cardiomyopathy	0.000956	0.0064	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—ALMS1—dilated cardiomyopathy	0.000951	0.00636	CbGpPWpGaD
Gemcitabine—SLC29A1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000948	0.00634	CbGpPWpGaD
Gemcitabine—SLC29A1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000948	0.00634	CbGpPWpGaD
Gemcitabine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000943	0.00219	CcSEcCtD
Gemcitabine—Pruritus—Lisinopril—dilated cardiomyopathy	0.00093	0.00216	CcSEcCtD
Gemcitabine—CDA—Metabolism—ANKRD1—dilated cardiomyopathy	0.000924	0.00618	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—ALMS1—dilated cardiomyopathy	0.000918	0.00614	CbGpPWpGaD
Gemcitabine—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000899	0.00209	CcSEcCtD
Gemcitabine—SLC29A1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.000881	0.00589	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.000873	0.00584	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—TAZ—dilated cardiomyopathy	0.000869	0.00581	CbGpPWpGaD
Gemcitabine—POLE—Mitotic M-M/G1 phases—TMPO—dilated cardiomyopathy	0.000868	0.00581	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000844	0.00565	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—TUBB—dilated cardiomyopathy	0.000836	0.00559	CbGpPWpGaD
Gemcitabine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000836	0.00194	CcSEcCtD
Gemcitabine—Rash—Lisinopril—dilated cardiomyopathy	0.000829	0.00193	CcSEcCtD
Gemcitabine—Dermatitis—Lisinopril—dilated cardiomyopathy	0.000828	0.00193	CcSEcCtD
Gemcitabine—Headache—Lisinopril—dilated cardiomyopathy	0.000823	0.00192	CcSEcCtD
Gemcitabine—RRM2—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000818	0.00547	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000814	0.00544	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000798	0.00534	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—SDHA—dilated cardiomyopathy	0.000786	0.00525	CbGpPWpGaD
Gemcitabine—POLE—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000785	0.00525	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—TUBB—dilated cardiomyopathy	0.000781	0.00522	CbGpPWpGaD
Gemcitabine—Nausea—Lisinopril—dilated cardiomyopathy	0.000781	0.00182	CcSEcCtD
Gemcitabine—POLA1—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.000778	0.0052	CbGpPWpGaD
Gemcitabine—DCK—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000764	0.00511	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—TUBB—dilated cardiomyopathy	0.000748	0.005	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—EMD—dilated cardiomyopathy	0.000745	0.00499	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.000732	0.00489	CbGpPWpGaD
Gemcitabine—POLE—Mitotic M-M/G1 phases—LMNA—dilated cardiomyopathy	0.000713	0.00477	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—ALMS1—dilated cardiomyopathy	0.000701	0.00469	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—ANKRD1—dilated cardiomyopathy	0.0007	0.00468	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—EMD—dilated cardiomyopathy	0.000696	0.00465	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000677	0.00452	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000672	0.0045	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—EMD—dilated cardiomyopathy	0.000667	0.00446	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—TAZ—dilated cardiomyopathy	0.000658	0.0044	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—ALMS1—dilated cardiomyopathy	0.000654	0.00437	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000649	0.00434	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—ALMS1—dilated cardiomyopathy	0.000627	0.00419	CbGpPWpGaD
Gemcitabine—POLA1—Mitotic M-M/G1 phases—TMPO—dilated cardiomyopathy	0.000619	0.00414	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—TMPO—dilated cardiomyopathy	0.000605	0.00405	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—TMPO—dilated cardiomyopathy	0.000601	0.00402	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—SDHA—dilated cardiomyopathy	0.000595	0.00398	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—TMPO—dilated cardiomyopathy	0.000581	0.00388	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—ANKRD1—dilated cardiomyopathy	0.000577	0.00386	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000573	0.00383	CbGpPWpGaD
Gemcitabine—POLA1—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000559	0.00374	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000556	0.00372	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000552	0.00369	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—TAZ—dilated cardiomyopathy	0.000542	0.00363	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—TAZ—dilated cardiomyopathy	0.000539	0.0036	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—ANKRD1—dilated cardiomyopathy	0.000539	0.0036	CbGpPWpGaD
Gemcitabine—TYMS—Retinoblastoma (RB) in Cancer—RAF1—dilated cardiomyopathy	0.000536	0.00358	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000533	0.00357	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000529	0.00354	CbGpPWpGaD
Gemcitabine—POLA1—Mitotic M-M/G1 phases—LMNA—dilated cardiomyopathy	0.000508	0.0034	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—TAZ—dilated cardiomyopathy	0.000507	0.00339	CbGpPWpGaD
Gemcitabine—RRM2—Cell Cycle—LMNA—dilated cardiomyopathy	0.000497	0.00332	CbGpPWpGaD
Gemcitabine—POLD1—Cell Cycle—LMNA—dilated cardiomyopathy	0.000494	0.0033	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—SDHA—dilated cardiomyopathy	0.00049	0.00328	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—SDHA—dilated cardiomyopathy	0.000487	0.00326	CbGpPWpGaD
Gemcitabine—POLE—Cell Cycle—LMNA—dilated cardiomyopathy	0.000477	0.00319	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000476	0.00318	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000463	0.00309	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000459	0.00307	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—SDHA—dilated cardiomyopathy	0.000458	0.00306	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000456	0.00305	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.00045	0.00301	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—TMPO—dilated cardiomyopathy	0.000443	0.00296	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000439	0.00294	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—PLN—dilated cardiomyopathy	0.000435	0.00291	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000431	0.00288	CbGpPWpGaD
Gemcitabine—TYMS—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000422	0.00282	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—TMPO—dilated cardiomyopathy	0.000414	0.00277	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—TMPO—dilated cardiomyopathy	0.000396	0.00265	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.00038	0.00254	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—ANKRD1—dilated cardiomyopathy	0.000378	0.00253	CbGpPWpGaD
Gemcitabine—ABCB1—Allograft Rejection—AGTR1—dilated cardiomyopathy	0.000366	0.00245	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle, Mitotic—LMNA—dilated cardiomyopathy	0.000364	0.00243	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000363	0.00243	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—TAZ—dilated cardiomyopathy	0.000355	0.00238	CbGpPWpGaD
Gemcitabine—RRM1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000346	0.00231	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—GPX1—dilated cardiomyopathy	0.000345	0.00231	CbGpPWpGaD
Gemcitabine—SLC28A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.00034	0.00227	CbGpPWpGaD
Gemcitabine—POLA1—Cell Cycle—LMNA—dilated cardiomyopathy	0.00034	0.00227	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—CD36—dilated cardiomyopathy	0.000336	0.00225	CbGpPWpGaD
Gemcitabine—TYMS—Cell Cycle—LMNA—dilated cardiomyopathy	0.000326	0.00218	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—SDHA—dilated cardiomyopathy	0.000321	0.00215	CbGpPWpGaD
Gemcitabine—ABCB1—Allograft Rejection—IL10—dilated cardiomyopathy	0.000306	0.00205	CbGpPWpGaD
Gemcitabine—CMPK1—Metabolism—AGT—dilated cardiomyopathy	0.000303	0.00203	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000298	0.00199	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	0.000286	0.00191	CbGpPWpGaD
Gemcitabine—ABCB1—Allograft Rejection—FASLG—dilated cardiomyopathy	0.000285	0.00191	CbGpPWpGaD
Gemcitabine—SLC29A2—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000277	0.00185	CbGpPWpGaD
Gemcitabine—ABCB1—Allograft Rejection—FAS—dilated cardiomyopathy	0.000275	0.00184	CbGpPWpGaD
Gemcitabine—SLC28A3—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000258	0.00172	CbGpPWpGaD
Gemcitabine—ABCC10—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000242	0.00162	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—GPX1—dilated cardiomyopathy	0.000213	0.00143	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—CD36—dilated cardiomyopathy	0.000208	0.00139	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000204	0.00137	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	0.000196	0.00131	CbGpPWpGaD
Gemcitabine—POLA1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000195	0.0013	CbGpPWpGaD
Gemcitabine—SLC29A1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	0.000192	0.00129	CbGpPWpGaD
Gemcitabine—CDA—Metabolism—AGT—dilated cardiomyopathy	0.000187	0.00125	CbGpPWpGaD
Gemcitabine—TYMS—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	0.000187	0.00125	CbGpPWpGaD
Gemcitabine—ABCB1—Transmembrane transport of small molecules—RYR2—dilated cardiomyopathy	0.000177	0.00119	CbGpPWpGaD
Gemcitabine—ABCB1—Transmembrane transport of small molecules—SLC22A5—dilated cardiomyopathy	0.000173	0.00115	CbGpPWpGaD
Gemcitabine—ABCB1—Transmembrane transport of small molecules—PLN—dilated cardiomyopathy	0.000173	0.00115	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—GPX1—dilated cardiomyopathy	0.000162	0.00108	CbGpPWpGaD
Gemcitabine—ABCB1—Transmembrane transport of small molecules—ABCC9—dilated cardiomyopathy	0.00016	0.00107	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—CD36—dilated cardiomyopathy	0.000158	0.00105	CbGpPWpGaD
Gemcitabine—RRM1—Metabolism—AGT—dilated cardiomyopathy	0.000142	0.000948	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000141	0.00094	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.000136	0.000907	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—GPX1—dilated cardiomyopathy	0.000133	0.000891	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000133	0.000889	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—GPX1—dilated cardiomyopathy	0.000132	0.000885	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—CD36—dilated cardiomyopathy	0.00013	0.000867	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—CD36—dilated cardiomyopathy	0.000129	0.000862	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—GPX1—dilated cardiomyopathy	0.000124	0.000832	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—CD36—dilated cardiomyopathy	0.000121	0.000811	CbGpPWpGaD
Gemcitabine—RRM2—Metabolism—AGT—dilated cardiomyopathy	0.000117	0.000781	CbGpPWpGaD
Gemcitabine—ABCB1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000117	0.00078	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—ANKRD1—dilated cardiomyopathy	0.000117	0.00078	CbGpPWpGaD
Gemcitabine—POLD1—Metabolism—AGT—dilated cardiomyopathy	0.000116	0.000776	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—TAZ—dilated cardiomyopathy	0.00011	0.000733	CbGpPWpGaD
Gemcitabine—DCK—Metabolism—AGT—dilated cardiomyopathy	0.000109	0.00073	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—SDHA—dilated cardiomyopathy	9.91e-05	0.000663	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	8.81e-05	0.000589	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—GPX1—dilated cardiomyopathy	8.73e-05	0.000584	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—CD36—dilated cardiomyopathy	8.5e-05	0.000568	CbGpPWpGaD
Gemcitabine—TYMS—Metabolism—AGT—dilated cardiomyopathy	7.65e-05	0.000512	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	6.04e-05	0.000404	CbGpPWpGaD
Gemcitabine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	5.76e-05	0.000385	CbGpPWpGaD
Gemcitabine—ABCB1—Transmembrane transport of small molecules—RAF1—dilated cardiomyopathy	3.5e-05	0.000234	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—GPX1—dilated cardiomyopathy	2.69e-05	0.00018	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—CD36—dilated cardiomyopathy	2.62e-05	0.000175	CbGpPWpGaD
Gemcitabine—ABCB1—Metabolism—AGT—dilated cardiomyopathy	2.36e-05	0.000158	CbGpPWpGaD
